OKYO Pharma (STU:OK10) Cyclically Adjusted PB Ratio: (As of Aug. 16, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:OK10 OKYO Pharma Ltd STU:OK10
24 GF Score
Price €2.16
! 2 Warning Signs
View Full Analysis

What is OKYO Pharma Cyclically Adjusted PB Ratio?

Note: If the price history is too short, we do not calculate current Cyclically Adjusted PB Ratio for this stock. All the historical data is shown as the company's primary share's data instead.

Shiller PE for Stocks: The True Measure of Stock Valuation


OKYO Pharma  (STU:OK10) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


OKYO Pharma Cyclically Adjusted PB Ratio Related Terms


OKYO Pharma Cyclically Adjusted PB Ratio Historical Data

* Premium members only.

The historical data trend for OKYO Pharma's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

OKYO Pharma Cyclically Adjusted PB Ratio Chart

OKYO Pharma Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 12.92 14.79 16.57 17.69

OKYO Pharma Semi-Annual Data
Sep16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24 Mar25 Sep25 Mar26
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 14.79 0.00 16.57 0.00 17.69

STU:OK10 vs ALPS, CGTX, INO: Cyclically Adjusted PB Ratio Comparison

For the Biotechnology subindustry, OKYO Pharma's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


OKYO Pharma Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, OKYO Pharma's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where OKYO Pharma's Cyclically Adjusted PB Ratio falls into.


STU:OK10
24GF Score
OKYO Pharma Ltd STU:OK10
Cyclically Adjusted PB Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

OKYO Pharma Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

OKYO Pharma's Cyclically Adjusted Book per Share for the fiscal year that ended in Mar26 is calculated as:

For example, OKYO Pharma's adjusted Book Value per Share data for the fiscal year that ended in Mar26 was:

Adj_Book=Book Value per Share/CPI of Mar26 (Change)*Current CPI (Mar26)
=0.263/140.8000*140.8000
=0.263

Current CPI (Mar26) = 140.8000.

OKYO Pharma Annual Data

Book Value per Share CPI Adj_Book
201703 0.168 102.700 0.230
201803 0.006 105.100 0.008
201903 0.001 107.000 0.001
202003 -0.013 108.600 -0.017
202103 0.432 109.700 0.554
202203 0.127 116.500 0.153
202303 -0.038 126.800 -0.042
202403 -0.162 131.600 -0.173
202503 -0.143 136.100 -0.148
202603 0.263 140.800 0.263

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


OKYO Pharma Business Description

Other Exchanges OKYO:USA
Address 14/15 Conduit Street, Floor 4, London, GBR, W1S 2XJ
OKYO Pharma Ltd is a biopharmaceutical company. The company is developing therapeutics to improve the lives of patients with inflammatory eye diseases and chronic pain. It offers solutions for various diseases such as Dry Eye Disease, Non-infectious Anterior Uveitis, Allergenic Conjunctivitis, Chronic Pain, and Ocular Pain.
24GF Score

Get the complete analysis for STU:OK10

Cyclically Adjusted PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.16
Price